Trial Profile
TEAM II: a randomised, multicentre, prospective, phase III trial investigating neoadjuvant hormonal therapy with exemestane for three versus six months (TEAM IIa) and/or the efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone receptor positive early breast cancer (TEAM IIb)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2022
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Ibandronic acid (Primary) ; Antineoplastics
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms TEAM-II; TEAM-IIa; TEAM-IIb
- 20 Apr 2022 Primary endpoint has not been met (disease-free survival (DFS), analyzed in the intention-to-treat population), as per Results published in the Journal of Clinical Oncology
- 20 Apr 2022 Results published in the Journal of Clinical Oncology
- 01 Oct 2013 Preliminary results presented at the 2013 European Cancer Congress.